Strategies to minimise budget impact and increase cost effectiveness of pathogen inactivation
Filip De Groof Consultant Cerus BV
Pathogen reduction of double dose platelet concentrates from pools of eight Buffy coats: product quality, safety and economic aspects
Dr. Konrad Rosskopf Dept. Transfusion Medicine University Hospital of Graz, Austria
Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany
Prof. Dr. Florian Kron Managing Director VITIS Healthcare group